安旭生物(688075) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 129,406,701.97, representing a year-on-year increase of 6.53%[4] - The net profit attributable to shareholders was CNY 70,190,798.47, reflecting a significant increase of 38.09% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 19,629,646.53, which is a remarkable increase of 134.82% year-on-year[4] - Total revenue for Q1 2024 reached CNY 129.41 million, an increase of 6.9% compared to CNY 121.48 million in Q1 2023[18] - Net profit for Q1 2024 was CNY 70.33 million, up 39.7% from CNY 50.38 million in Q1 2023[19] - Earnings per share for Q1 2024 were CNY 0.55, compared to CNY 0.40 in Q1 2023, reflecting a 37.5% increase[20] Cash Flow and Assets - The net cash flow from operating activities was CNY 1,008,618.28, showing a decline of 100.84% compared to the previous year[4] - The company reported a decrease in cash flow primarily due to tax payments and employee bonuses in the previous year[8] - As of March 31, 2024, the company's cash and cash equivalents amounted to RMB 675,427,076.63, an increase from RMB 337,355,385.11 on December 31, 2023, representing a growth of 100.4%[15] - The total current assets reached RMB 4,878,653,999.22, compared to RMB 4,811,722,641.50 at the end of 2023, indicating a slight increase of 1.4%[15] - The company reported a total cash inflow from operating activities of 167,094,020.34, while cash outflow was 166,085,402.06, indicating a tight operational cash flow[22] - The company received tax refunds totaling 9,878,317.12, contributing positively to cash inflows[22] - Cash inflow from investment recoveries was 1,540,333,850.54, showing strong investment performance[22] - The company incurred cash outflows of 2,000,000.00 for debt repayment during the financing activities[23] - The net cash flow from financing activities was -2,000,000.00, indicating a reduction in cash due to debt servicing[23] - The impact of exchange rate changes on cash and cash equivalents was -436,936.44, reflecting currency fluctuations[23] - The company reported a significant increase in cash and cash equivalents by 321,664,962.88 during the quarter[23] Research and Development - The total R&D investment was CNY 19,840,217.39, which decreased by 16.54% year-on-year, accounting for 15.33% of operating revenue[4] - Research and development expenses were CNY 19.84 million, down from CNY 23.77 million, a decrease of 16.3% year-over-year[19] Shareholder Information - The company reported a total of 34,150,290 shares held by Hangzhou Aixi Holdings, accounting for 26.87% of total shares[10] - The second-largest shareholder, Ling Shisheng, holds 31,929,520 shares, representing 25.12% of total shares[10] - The company has not reported any significant changes in the top 10 shareholders due to the transfer of shares[13] - The company has a total of 1,270,832 shares held by Minsheng Securities, which is 1.00% of total shares[12] Future Outlook - The company has not disclosed any new strategies or future outlook in the current report[13] Other Financial Metrics - The basic and diluted earnings per share were both CNY 0.55, marking an increase of 38.09% compared to the same period last year[4] - The weighted average return on net assets was 0.01%, reflecting an increase of 46.71% year-on-year[4] - Total operating costs decreased to CNY 112.89 million from CNY 115.41 million, a reduction of 2.2% year-over-year[19] - Non-current assets totaled CNY 976.47 million, slightly down from CNY 977.82 million in the previous quarter[17] - Total assets increased to CNY 5.86 billion from CNY 5.79 billion, marking a growth of 1.2%[17] - Total liabilities decreased to CNY 680.23 million from CNY 683.83 million, a decline of 0.8%[17] - Deferred income tax assets rose to CNY 168.20 million from CNY 164.40 million, an increase of 2.2%[17] - Non-recurring gains and losses amounted to CNY 50,561,151.94 after tax, with significant contributions from government subsidies and other non-operating income[7]